Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.75 |
| ▸ | BTK | Q06187 | 4/20 | 0.73 |
| ▸ | SYK | P43405 | 2/20 | 0.61 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.60 |
| ▸ | TTK | P33981 | 6/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.56 |
| ▸ | PAK4 | O96013 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12085388 | 0.89 | JAK3 (0.73) | JAK3BTKSYKPTK2TTK | |
| SCHEMBL1019228 | 0.89 | JAK3 (0.66) | JAK3BTKSYKPTK2TTK | |
| SCHEMBL30298492 | 0.89 | JAK3 (0.65) | JAK3BTKSYKPTK2TTK | |
| SCHEMBL24243321 | 0.87 | JAK3 (0.76) | JAK3BTKSYKPTK2TTK | |
| SCHEMBL22496867 | 0.86 | JAK3 (1.00) | JAK3BTKSYKPTK2EGFR | |
| SCHEMBL17856870 | 0.86 | TTK (0.73) | JAK3BTKSYKPTK2TTK | |
| SCHEMBL22496724 | 0.85 | JAK3 (1.00) | JAK3BTKEGFR | |
| SCHEMBL22497007 | 0.85 | JAK3 (1.00) | JAK3BTKEGFR | |
| SCHEMBL22496725 | 0.85 | JAK3 (1.00) | JAK3BTKEGFR | |
| SCHEMBL12085415 | 0.85 | JAK3 (0.58) | JAK3BTKSYKPTK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | JAK3 6/4885BTK 2/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.